Galectin Therapeutics Inc.
GALTHealthcare|Biotechnology|US
$3.14
+0.15 (+5.19%)
Cash / Share
$0.20
Financials
Financial Snapshot
Market Cap
$206.8M
Enterprise Value
$331.2M
Revenue (TTM)
$0.00
Net Income (TTM)
-$27.8M
Cash & Investments
$13.3M
Net Cash
-$124.4M
Free Cash Flow (TTM)
-$15.9M
Operating CF (TTM)
-$15.9M
Debt/Equity
-1.01
Cash Runway & Burn Rate
Cash on Hand
$13.3M
Quarterly Burn
$4.0M
Monthly Burn
$1.3M
Est. Runway
~3.3 quarters
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Investments | $15.4M | $3.1M | $8.3M | $47.5M | $27.1M | $39.6M | $18.6M | $25.7M | $15.1M | $17.7M | $13.3M | |
| Operating Cash Flow | -$16.4M | -$15.9M | -$10.2M | -$10.8M | -$20.6M | -$24.3M | -$31.1M | -$33.0M | -$41.8M | -$23.9M | -$15.9M | |
| Free Cash Flow | -$16.4M | -$15.9M | -$10.2M | -$10.8M | -$20.6M | -$24.3M | -$31.1M | -$33.0M | -$41.8M | -$23.9M | -$15.9M | |
| Capital Expenditure | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Financing Cash Flow | $5.9M | $3.6M | $15.4M | $50.1M | $263.0K | $36.8M | $10.0M | $40.0M | $31.2M | $26.5M | $15.4M |
R&D Spending
R&D (TTM)
$8.9M
R&D Intensity
—
R&D Growth vs Prior
-37.6%
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| R&D Expense | $15.3M | $11.7M | $6.5M | $7.5M | $18.0M | $23.8M | $31.7M | $32.1M | $36.6M | $14.3M | $8.9M | |
| SG&A | $6.2M | $4.5M | $7.1M | $6.0M | $5.5M | $6.4M | $6.6M | $5.9M | $5.9M | $5.8M | $6.7M |
Income Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Cost of Revenue | $7.0K | $1.0K | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Gross Profit | -$7.0K | -$1.0K | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| R&D | $15.3M | $11.7M | $6.5M | $7.5M | $18.0M | $23.8M | $31.7M | $32.1M | $36.6M | $14.3M | $8.9M | |
| SG&A | $6.2M | $4.5M | $7.1M | $6.0M | $5.5M | $6.4M | $6.6M | $5.9M | $5.9M | $5.8M | $6.7M | |
| Operating Income | -$21.5M | -$16.2M | -$13.6M | -$13.4M | -$23.4M | -$30.2M | -$38.4M | -$38.1M | -$42.4M | -$20.1M | -$15.6M | |
| Interest Expense | $0.00 | $12.0K | $336.0K | $87.0K | $87.0K | $489.0K | $1.0M | $2.8M | $5.5M | $7.3M | $7.8M | |
| Pretax Income | -$21.4M | -$16.2M | -$13.9M | -$13.3M | -$23.5M | -$30.5M | -$38.8M | -$41.1M | -$47.0M | -$30.8M | -$27.8M | |
| Net Income | -$21.4M | -$16.2M | -$13.9M | -$13.3M | -$23.5M | -$30.5M | -$38.8M | -$41.1M | -$47.0M | -$30.8M | -$27.8M | |
| EPS (Diluted) | -0.73 | -0.46 | -0.35 | -0.39 | -0.41 | -0.52 | -0.65 | -0.74 | -0.76 | -0.48 | -0.43 | |
| EBITDA | -$21.5M | -$16.2M | -$13.6M | -$13.2M | -$23.3M | -$30.0M | -$37.7M | -$38.2M | -$41.5M | -$23.5M | -$13.8M | |
| Shares Out. (M) | 29.22 | 35.52 | 39.41 | 52.24 | 57.03 | 58.53 | 59.39 | 60.16 | 62.31 | 63.90 | 65.88 |
Balance Sheet
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $15.4M | $3.1M | $8.3M | $47.5M | $27.1M | $39.6M | $18.6M | $25.7M | $15.1M | $17.7M | $13.3M | |
| Short-Term Investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Current Assets | $15.8M | $3.8M | $8.8M | $48.2M | $29.5M | $41.8M | $20.6M | $27.7M | $17.3M | $19.4M | $14.7M | |
| Total Assets | $15.8M | $4.2M | $9.0M | $48.5M | $29.6M | $41.8M | $21.3M | $28.2M | $17.5M | $19.5M | $14.8M | |
| Total Current Liabilities | $3.8M | $3.0M | $2.1M | $2.8M | $5.4M | $9.0M | $13.0M | $15.7M | $35.4M | $8.0M | $151.6M | |
| Long-Term Debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $29.0M | $39.8M | $71.7M | $85.1M | $133.7M | $0.00 | |
| Total Liabilities | $3.8M | $3.0M | $2.1M | $2.9M | $5.4M | $39.2M | $53.5M | $88.4M | $120.6M | $145.7M | $151.7M | |
| Stockholders' Equity | $12.0M | $1.2M | $6.9M | $45.6M | $24.2M | $2.6M | -$32.2M | -$60.2M | -$103.1M | -$126.2M | -$136.9M | |
| Retained Earnings | -$163.7M | -$181.2M | -$196.2M | -$216.4M | -$240.0M | -$270.7M | -$309.6M | -$354.4M | -$401.6M | -$432.5M | -$446.8M |
Cash Flow Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$16.4M | -$15.9M | -$10.2M | -$10.8M | -$20.6M | -$24.3M | -$31.1M | -$33.0M | -$41.8M | -$23.9M | -$15.9M | |
| Capital Expenditure | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Free Cash Flow | -$16.4M | -$15.9M | -$10.2M | -$10.8M | -$20.6M | -$24.3M | -$31.1M | -$33.0M | -$41.8M | -$23.9M | -$15.9M | |
| Investing Cash Flow | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Financing Cash Flow | $5.9M | $3.6M | $15.4M | $50.1M | $263.0K | $36.8M | $10.0M | $40.0M | $31.2M | $26.5M | $15.4M | |
| Issuance of Stock | $5.9M | $3.6M | $15.4M | $50.5M | $263.0K | $6.8M | $0.00 | $0.00 | $1.2M | $5.5M | $4.9M | |
| Repurchase of Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Net Debt Issuance | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $30.0M | $10.0M | $30.0M | $30.0M | $21.0M | $10.0M | |
| Stock Based Comp. | $2.5M | $1.1M | $4.4M | $1.7M | $1.8M | $2.1M | $2.9M | $2.3M | $2.4M | $1.7M | $2.3M | |
| Net Change in Cash | -$10.5M | -$12.3M | $5.2M | $39.2M | -$20.3M | $12.5M | -$21.1M | $7.1M | -$10.5M | $2.6M | -$502.0K |
Dilution Tracker
Shares Outstanding
66M
5-Year Share Growth
+12.1%
Stock Issuance (TTM)
$4.9M
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 29.22 | 35.52 | 39.41 | 52.24 | 57.03 | 58.53 | 59.39 | 60.16 | 62.31 | 63.90 | 65.88 | |
| Change vs Prior % | — | 21.6% | 11.0% | 32.5% | 9.2% | 2.6% | 1.5% | 1.3% | 3.6% | 2.6% | 3.1% | |
| Stock Issuance | $5.9M | $3.6M | $15.4M | $50.5M | $263.0K | $6.8M | $0.00 | $0.00 | $1.2M | $5.5M | $4.9M | |
| Stock Repurchase | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $2.5M | $1.1M | $4.4M | $1.7M | $1.8M | $2.1M | $2.9M | $2.3M | $2.4M | $1.7M | $2.3M |
Margins & Profitability
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE % | -178.4% | -1360.9% | -201.5% | -29.2% | -97.0% | -1166.9% | 120.4% | 68.2% | 45.6% | 24.4% | 21.5% | |
| ROA % | -135.7% | -390.2% | -154.3% | -27.4% | -79.3% | -73.0% | -182.2% | -145.6% | -268.9% | -157.9% | -187.8% | |
| ROIC % | -178.8% | -1361.9% | -197.2% | -29.4% | -96.7% | -92.0% | -461.3% | -302.9% | -1317.0% | -174.3% | -1613.8% |
Growth (Year over Year)
Fiscal years. Rising share count growth means dilution.
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Gross Profit | 0.0% | 85.7% | 100.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Operating Income | -7.0% | 24.4% | 16.3% | 1.2% | -74.5% | -28.7% | -27.1% | 0.7% | -11.5% | 52.7% | |
| Net Income | -7.0% | 24.3% | 14.4% | 4.4% | -76.5% | -30.1% | -27.0% | -5.9% | -14.6% | 34.5% | |
| EPS (Diluted) | 12.0% | 37.0% | 23.9% | -11.4% | -5.1% | -26.8% | -25.0% | -13.8% | -2.7% | 36.8% | |
| Operating Cash Flow | 3.4% | 3.2% | 35.9% | -6.6% | -89.9% | -18.0% | -27.8% | -6.1% | -26.7% | 42.8% | |
| Free Cash Flow | 3.4% | 3.2% | 35.9% | -6.6% | -89.9% | -18.0% | -27.8% | -6.1% | -26.7% | 42.8% | |
| R&D Expense | 16.9% | -23.5% | -44.8% | 15.4% | 140.7% | 32.5% | 33.2% | 1.2% | 13.8% | -60.9% | |
| SG&A Expense | -11.6% | -26.5% | 57.6% | -16.3% | -8.4% | 16.3% | 4.0% | -10.2% | -1.3% | -1.1% | |
| Total Assets | -40.2% | -73.7% | 116.4% | 438.2% | -38.9% | 41.3% | -49.1% | 32.5% | -38.0% | 11.6% | |
| Book Value / Share | -60.4% | -91.8% | 421.1% | 398.7% | -51.4% | -89.5% | -1312.8% | -84.7% | -65.2% | -19.4% | |
| Debt | 0.0% | 0.0% | 0.0% | 0.0% | 12.8% | 65936.4% | 37.2% | 80.1% | 48.0% | 25.9% | |
| Diluted Shares | 21.1% | 21.6% | 11.0% | 32.5% | 9.2% | 2.6% | 1.5% | 1.3% | 3.6% | 2.6% |
Valuation
P/E (TTM)At Loss
P/S0.00
P/B-1.51
10Y Low / Med / High2.38 / 19.60 / 99.45
EV/EBITDAAt Loss
EV/Revenue0.00
P/FCFAt Loss
Intrinsic Value Models (per share)
Cash / Share
$0.20
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio | -1.34 | -7.26 | -9.80 | -7.33 | -5.46 | -3.98 | -1.74 | -2.24 | -1.70 | -8.67 | -7.35 | |
| P/S Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| P/B Ratio | 2.38 | 99.45 | 19.60 | 3.28 | 5.28 | 46.31 | -2.08 | -1.66 | -0.78 | -2.11 | -1.51 | |
| EV/EBITDA | -0.62 | -7.12 | -9.36 | -7.74 | -4.31 | -3.69 | -2.34 | -3.82 | -4.14 | -16.28 | -24.08 | |
| EV/Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Analyst Estimates & Quality
Altman Z-Score
-55.53
Distress
Piotroski F-Score
2
Weak
Forward Estimates (consensus)
| Metric | FY2026 | FY2027 | FY2028 |
|---|---|---|---|
| Revenue | $179.7M | $385.2M | $572.2M |
| Net Income | -$19.2M | -$14.7M | -$67.7M |
| EPS | $-0.30 | $-0.23 | $-1.06 |
| # Analysts (EPS) | 1 | 1 | 1 |